艾迪藥業(688488.SH):第一期員工持股計劃完成非交易過户並出售完畢
格隆匯5月11日丨艾迪藥業(688488.SH)公佈,截至公吿披露日,江蘇艾迪藥業股份有限公司已完成第一期員工持股計劃非交易過户及剩餘股份出售,其中非交易過户股份數量100,892股,集中競價交易方式出售股份數量1,708股,持股計劃可提前終止。
根據《江蘇艾迪藥業股份有限公司第一期員工持股計劃》規定,本次持股計劃所獲標的股票的鎖定期為12個月,自公司公吿最後一筆標的股票登記過户至該員工持股計劃名下之日起算,即2021年5月6日至2022年5月5日,2022年5月6日鎖定期屆滿。
根據本次員工持股計劃的相關規定,持股計劃的鎖定期滿後,當員工持股計劃所持標的股票全部出售或者非交易過户至員工個人證券賬户名下後,員工持股計劃可提前終止;因此公司第一期員工持股計劃實施完畢並終止,後續將進行資產的清算和收益分配等工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.